Literature DB >> 15744636

Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression.

M Schürks, M Overlack, U Bonnet.   

Abstract

Naltrexone is frequently used for the treatment of opioid or alcohol dependence. However, the reports on its potential to worsen affective disorders are contradicting. Here we report on a patient with combined alcohol and opioid dependence whose co-morbid major depression deteriorated reversibly and repeatedly under naltrexone. By exchanging buprenorphine for naltrexone, his depression and craving for alcohol and opioids disappeared. This underlines the close interaction between depression, substance dependence and the opioid system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15744636     DOI: 10.1055/s-2005-837812

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  4 in total

1.  Problem drinking and low-dose naltrexone-assisted opioid detoxification.

Authors:  Paolo Mannelli; Kathleen Peindl; Ashwin A Patkar; Li-Tzy Wu; Haresh M Tharwani; David A Gorelick
Journal:  J Stud Alcohol Drugs       Date:  2011-05       Impact factor: 2.582

2.  Sex differences in affective response to opioid withdrawal during adolescence.

Authors:  Stephen R Hodgson; Rebecca S Hofford; Kris W Roberts; Dvora Eitan; Paul J Wellman; Shoshana Eitan
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

3.  Different affective response to opioid withdrawal in adolescent and adult mice.

Authors:  Stephen R Hodgson; Rebecca S Hofford; Paul J Wellman; Shoshana Eitan
Journal:  Life Sci       Date:  2008-11-12       Impact factor: 5.037

4.  Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

Authors:  John D Roache; Martina Pavlicova; Aimee Campbell; Tse-Hwei Choo; Michelle Peavy; Andrea S Kermack; Edward V Nunes; John Rotrosen
Journal:  Alcohol Clin Exp Res       Date:  2021-11-23       Impact factor: 3.455

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.